Thursday, August 25, 2022
ENDRA Life Sciences Inc., an innovative company specializing in imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), is excited to announce the issuance of European Patent No. 3730041 (referred to as the '041 patent) by the European Patent Office. This patent, titled "System for Estimating Fractional Fat Content of an Object," safeguards ENDRA's TAEUS system, which enables the calculation of fat concentration in the human body through multiple thermoacoustic measurements. The '041 patent is closely related to U.S. patent 9980677B1 and Chinese patent ZL201880050042.2.
"We are delighted to have received this latest patent in Europe, which aligns with our strategy of developing optimized hybrid ultrasound and thermoacoustic imaging systems and expanding the potential applications of our proprietary TAEUS® technology in areas where there are unmet clinical needs," commented Francois Michelon, Chairman, and Chief Executive Officer of ENDRA. "We are continuously bolstering our intellectual property portfolio to safeguard our technology in key global markets. Currently, our portfolio comprises 54 patents issued worldwide, including eight in Europe."
This European patent issuance reinforces ENDRA's commitment to advancing its groundbreaking TAEUS technology and further solidifies its position as a leader in the field of imaging technologies. By protecting their intellectual property, ENDRA aims to bring innovative and effective solutions to clinical settings and address critical unmet needs.